The move comes just as the CDC recommends adding Covid-19 jabs to regular immunization schedules. Bristol Myers Squibb lined up a date with the FDA to expand the footprint of mavacamten , the drug it obtained from the $13 billion buyout of MyoKardia now marketed as Camzyos . The ...